All News
"Get rid of partial response. Why would you want to see an oncologist who say I can get risk part of your cancer? Wouldn't you want to get rid of the whole cancer!" - Dr. M Petri on how we should view lupus nephritis #ACR23 @rheumnow #MeetExpert
TheDaoIndex KDAO2011 ( View Tweet)
Proof of concept for cCAR BCMA CD19 - safely eliminated all autoabs, reset B cell/humoral immune system, & delivered long-term, med-free remission in 1 dose in LN and SLE. More studies needed! #ACR Abs 1493 @rheumnow https://t.co/sT68cN3TKe
Dr. Rachel Tate ( View Tweet)
UTSW Dallas study: Health literacy may be essential limiting factor for families w/ children w/ SLE. Other critical barriers to patient care include food security and living costs such as transportation, housing, and utilities. #ACR23 Abs #1029 https://t.co/jtnIgLZQfC @rheumnow https://t.co/A1zr8quSdd
Dr. Rachel Tate ( View Tweet)
LV mass higher in pts with SLE nephritis.Nested case-control study 48 SLE pts +/- LN. LV mass higher w/LN (66.9 g/m2) vs pts w/o LN (54.8 g/m2, p=0.035). Higher LV mass may increase risk for CV events as CHF, arrhythmias and CV mortality. @RheumNow #ACR23 abst#1447
TheDaoIndex KDAO2011 ( View Tweet)
Real World SLE Rx patterns from the SPOCS cohort. 70+% IFN high, 81% on antimalarials, 21% biologics, and 55% IS, 65% GCs. High IFN pts had more IS and steroid use. 45+% still on GCs at 12 months despite avail of new therapeutics @RheumNow #ACR23 abst#0592
TheDaoIndex KDAO2011 ( View Tweet)
Vasc Events in Danish Cohort: 3178 SLE pts matched to 60K controls. MI in SLE 2.9% vs 1.4%, cerebrovascular dz 7% vs 2.7%, & PVD 5.5% vs 1.4%. IRR ranged 1.7-7.6. Female SLE pts had 3-5X risk for CVE, Male pts 6-8X risk. @RheumNow #ACR23 abst#1442 https://t.co/PapDiJ0shJ
TheDaoIndex KDAO2011 ( View Tweet)
Obintuzumab in Lupus Nephritis
Researchers found that treatment with obinutuzumab was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis.
https://t.co/Sbh6k6XKjz https://t.co/aDbLUh7WtM
Dr. John Cush RheumNow ( View Tweet)
ABS0122 at #ACR23
⭐️Risk of acute MI, stroke & death signif ⬆️ among RA/SLE pts w/ depress, anxiety, &/or PTSD vs w/o both RA/SLE
➡️U.S. pts: 3825 RA, 1862 SLE --> 1790 w/ above mental health dz, no prior CVD
➡️HR 1.28 after adjusting for🚬, obesity, & comorbidities
@RheumNow https://t.co/sXMFtaKmYB
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
TM02 @ #ACR23:
19yo F w/ SLE p/w 1w DOE
PMHx: SLE (malar, LN, AIHA, ITP) on HCQ x 10yrs
Dx?
HCQ-induced CM (curvilinear bodies, vacuolar degen)
⭐️RF for HCQ-induced cardio-toxicity:
- older age, F
- HCQ > 10 yrs, ⬆️ daily dose
- hx of cardiac dz
- renal insuffic
@RheumNow https://t.co/GgzB2Chgra
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great work by @Yuz6Yusof
ANA positive and diagnosis , prediction tool to rule out/ in autoimmune pathology.
1-High interferon score.
2-FH autoimmune disease.
3- More criteria.
?Monogenic error of immune system , ?genome assessment .
@RheumNow , Daily recap
Nouf Al hemmadi ( View Tweet)
I vote for the ❤️
Several abstracts evaluated cardiovascular event prevalence and screening tools using ECHO, carotid ultrasound as current CV risk calculators are inadequate when assessing SLE CV risk. See my blog - just published @RheumNow
https://t.co/XLc0YHtJ0B https://t.co/oF0fXBRM6O
TheDaoIndex KDAO2011 ( View Tweet)
Sunday recap @RheumNow
Very interesting abstracts:
https://t.co/BX8bDSX1M3
1- Fecal calprotectin in SpA population.
2-SLE; high or low steroids? Rapid or slow taper?
3-Molecular biomarkers for PAH in SLE.
4-Repeating imaging in ? Chronic back pain?
And others …….
Nouf Al hemmadi ( View Tweet)
#ACR23 Abstr#0784 Beyond renal response, let’s also focus on kidney function and Steroid-sparing effect. Post-hoc analysis of Phase 2 RCT showed Obinutuzumab preserved eGFR by 4ml/min/1.73m2/year with greater number of pts achieving <7.5mg/d of prednisolone bs PBO @RheumNowNews https://t.co/2hW74UF1ta
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0590 Graphical Abstract makes it easy to follow 👏. Data using EHR showed that in #SLE with Diabetes, SGLT2-i vs DPP4-i was associated with reduced risks of developing AKI, CKD, ESRD, hospitalisation, and heart failure. Genital infection is common @RheumNowNews https://t.co/Iku6LqoYVb
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0571 As there is a genetic predisposition to #SLE, can polygenic risk score distinguish SLE vs ANA+ with no disease? A study in European ancestry showed modest discrimination (AUC: 0.66). This showed other contributors are vital in SLE development @RheumNowNews https://t.co/qiFOlOxq5r
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0785 So many debates re: HCQ dose 5mg/kg/d vs 6.5mg/kg/d - could blood monitoring help? A cohort study showed HCQ levels 750-1100 ng/mL was associated with reduced risk of #lupus activity by 76-90%. Need validation & assoc with retinal toxicity risk @RheumNowNews https://t.co/oRCHUG2dVA
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0548 Is there a risk prediction tool to help exclude non-immune pathology for Rheumatologists with newly referred ANA+? 3-yr data showed 3 BL markers: IFN score B, criteria No & FH of RMD had 98% specificity. Cd help inform early Tx trials in High Risk @RheumNowNews https://t.co/DCAg4EwM9d
Md Yuzaiful Md Yusof ( View Tweet)
Or to quote the great Murray Urowitz @UHN "a #lupus pregnancy has four trimesters"! #ACR23 https://t.co/Iw2S81tiTH
Ian N Bruce ( View Tweet)
✅ Question to YOU attending #ACR23 ➡️ We're almost at the end of 2023 ⌛and many great #lupus data are being presented at @ACRheum Convergence 2023 in San Diego 👍 What would YOU update/change 🔄 regarding the management of #lupus in 2024 compared to 2023? 🧭 https://t.co/xpSXjuDjyr
Laurent ARNAUD ( View Tweet)
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Adela Castro AdelaCastro222 ( View Tweet)